FIELD: medicine.
SUBSTANCE: present invention relates to a macrocycle of the formula (I) or to its pharmaceutically acceptable salt, to a pharmaceutical composition containing them, and to their use in the inhibition of activity of tropomyosin-receptor kinase A (hereinafter – TrkA-kinase) and in the treatment of diseases mediated by TrkA-kinase.
, where X is selected from a group containing of a bond, -O-, -S-, and -NR4-; Y is selected from a group consisting of 
and 
, where “*” is an end of the group Y, attached to an aminopyrazolopyrimidine ring, and R1-R5, m, n, Cy have values specified in the claims.
EFFECT: development of a new effective inhibitor of TrkA-kinase activity.
26 cl, 2 tbl, 37 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| ANILINE PYRIMIDINE DERIVATIVES AND USE THEREOF | 2016 |
|
RU2734849C2 |
| SELECTIVE KINASE JAK1 INHIBITOR | 2020 |
|
RU2818002C2 |
| SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | 2014 |
|
RU2671212C2 |
| PYRROLOPYRIMIDINE COMPOUND | 2015 |
|
RU2701206C2 |
| METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
| NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
